), a therapeutic and diagnostic devices maker, achieved a milestone
for its tumor-zapping NanoKnife System, which delivered positive
results in a clinical study. Based on this success story, the
physicians concluded that the NanoKnife System is safe for treating
liver tumors located near blood vessels.
Data from the study, conducted by doctors at the MemorialSloan
Kettering Cancer Center, was published in the
Journal of the American College of Surgeons
under the title "Ablation of Perivascular Hepatic Malignant Tumors
with Irreversible Electroporation".
The NanoKnife System was used in 28 patients with 65 tumors,
about 1 cm in size and located in close proximity to blood vessels.
The study was carried out between January 1 and November 2, 2011.
There were no treatment-related deaths and the morbidity rate was
3%. Blood vessels adjacent to the treated tumor were found to be
healthy after the procedure in all patients with the exception of
After a follow-up of six months, the rate of disease incidence
was nil in roughly 96% of the patients and the tumors did not recur
in the same place in 95% of the cases. Moreover, the pain reduced
and daily dosage of narcotic was lowered after 90 days. However,
physicians at the center asserted that larger studies and
follow-ups should be conducted to ascertain long-term patient
A separate study called "Irreversible Electroporation Therapy in
the Management of Locally Advanced Pancreatic Adenocarcinoma"
regarding data presented on the NanoKnife at the Society of
Surgical Oncology (SSO) in March 2012 was published in the
The NanoKnife System is used for the surgical ablation of soft
tissue. However, the product has not received approval for treating
any particular ailment. AngioDynamics is aggressively seeking
regulatory approval for the system in additional indications
including pancreatic cancer.
Increased demand for the NanoKnife device is driving revenues at
the AngioDynamics' soft Oncology division. Thus, NanoKnife remains
the life blood for the company, which is looking to expand the
label to broaden its commercial opportunity. AngioDynamics has been
ramping up research and development (R&D) investments to expand
its product portfolio and support the ongoing clinical studies of
NanoKnife and vascular product development programs.
AngioDynamics has a leading position in several of its operating
segments including angiographic products and thrombolytic catheters
and products. However, its product lines face strong challenges
from the competitive offerings of its larger rivals such as
C. R. Bard
Moreover, AngioDynamics is exposed to pricing headwinds stemming
from lower selling prices of some access and peripheral vascular
products. We currently have a Neutral recommendation on the
company, supported by a short-term Zacks #3 Rank (Hold) rating.
ANGIODYNAMICS (ANGO): Free Stock Analysis
BARD C R INC (BCR): Free Stock Analysis Report
To read this article on Zacks.com click here.